Key Narmafotinib Patent Granted in the U.S.

Core Viewpoint - Amplia Therapeutics Limited has received a key patent grant for narmafotinib, enhancing its intellectual property protection and extending it to at least 2040 in several jurisdictions [1][2][5]. Group 1: Patent and Intellectual Property - The US Patent and Trademark Office has granted a patent for a specific form of narmafotinib, which is crucial for the company's clinical development [1][2]. - The patent has also been granted in significant markets including Europe, Japan, India, Korea, and Australia, with ongoing reviews in other regions [2]. Group 2: Product Development - Narmafotinib (AMP945) is a potent FAK inhibitor targeting pancreatic cancer, showing promising results in preclinical studies [4]. - The drug is currently in the ACCENT clinical trial, demonstrating a confirmed response rate of 33%, which is higher than the 23% benchmark from the MPACT study [4]. - An interim median progression-free survival (PFS) of 7.6 months has been reported in the ACCENT trial [4]. - A second trial, AMPLICITY, is underway, investigating narmafotinib in combination with FOLFIRINOX for advanced pancreatic cancer patients [4]. Group 3: Company Overview - Amplia Therapeutics is focused on developing FAK inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers like pancreatic and ovarian cancer [3].